Ivan J Stone
Overview
Explore the profile of Ivan J Stone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazahreh R, Mason M, Gosink J, Olson D, Thurman R, Hale C, et al.
Mol Cancer Ther
. 2023 Feb;
22(4):421-434.
PMID: 36800443
SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of a humanized antibody, hL49, with high...
2.
Hamilton J, Pires T, Mitchell J, Cochran J, Emmerton K, Zaval M, et al.
ChemMedChem
. 2020 Dec;
16(7):1077-1081.
PMID: 33369163
Tubulysins have emerged in recent years as a compelling drug class for delivery to tumor cells via antibodies. The ability of this drug class to exert bystander activity while retaining...
3.
Trang V, Zhang X, Yumul R, Zeng W, Stone I, Wo S, et al.
Nat Biotechnol
. 2019 May;
37(7):761-765.
PMID: 31133742
The use of monoclonal antibodies in cancer therapy is limited by their cross-reactivity to healthy tissue. Tumor targeting has been improved by generating masked antibodies that are selectively activated in...
4.
Li F, Sutherland M, Yu C, Walter R, Westendorf L, Valliere-Douglass J, et al.
Mol Cancer Ther
. 2017 Nov;
17(2):554-564.
PMID: 29142066
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the...
5.
Li F, Ulrich M, Jonas M, Stone I, Linares G, Zhang X, et al.
Mol Cancer Ther
. 2017 Mar;
16(7):1347-1354.
PMID: 28341790
The primary mechanism of antibody-drug conjugates (ADC) is targeted delivery of a cytotoxic payload to tumor cells via cancer-associated membrane receptors. However, the tumor microenvironment likely plays a role in...
6.
Burke P, Hamilton J, Jeffrey S, Hunter J, Doronina S, Okeley N, et al.
Mol Cancer Ther
. 2017 Jan;
16(1):116-123.
PMID: 28062707
The emergence of antibody-drug conjugates (ADC), such as brentuximab vedotin and ado-trastuzumab emtansine, has led to increased efforts to identify new payloads and develop improved drug-linker technologies. Most antibody payloads...
7.
Burke P, Hamilton J, Pires T, Setter J, Hunter J, Cochran J, et al.
Mol Cancer Ther
. 2016 Mar;
15(5):938-45.
PMID: 26944920
A quaternary ammonium-based drug-linker has been developed to expand the scope of antibody-drug conjugate (ADC) payloads to include tertiary amines, a functional group commonly present in biologically active compounds. The...
8.
Jeffrey S, Burke P, Lyon R, Meyer D, Sussman D, Anderson M, et al.
Bioconjug Chem
. 2013 Jul;
24(7):1256-63.
PMID: 23808985
A highly cytotoxic DNA cross-linking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines or, site-specifically, through engineered cysteines...
9.
Oflazoglu E, Stone I, Gordon K, Wood C, Repasky E, Grewal I, et al.
Clin Cancer Res
. 2008 Sep;
14(19):6171-80.
PMID: 18809969
Purpose: The antitubulin agent monomethyl auristatin F (MMAF) induces potent antitumor effects when conjugated via protease cleavable linkers to antibodies targeting internalizing, tumor-specific cell surface antigens. Humanized 1F6 (h1F6) is...
10.
Bodensteiner K, Stone I, Ghiraldi L
J Gen Psychol
. 2008 Jul;
135(3):271-86.
PMID: 18649493
Young (2-4 months) and aged (14-16 months) male Swiss-Webster albino mice (n = 7 per group) were subcutaneously injected with 20 mg/kg/day dehydroepiandrosterone sulfate (DHEAS), progesterone (P), DHEAS + P,...